Skip to content

US · CRDL · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Cardiol Therapeutics Inc. (CRDL) intrinsic value and stock valuation

$0.86as of 2026-11-21 · Mkt cap 154.46M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cardiol Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values CRDL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CRDL’s statements →

Cardiol Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Oakville, ON L6H 0G5 cardiolrx.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-33.82M
20172025
Free cash flow
-$-23.88M
20172025
Total equity
$17.9M+6.1% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$60K
Operating income-$-34.32M-$-40.28M-$-22.47M-$-30.49M-$-30.57M
Net income-$-33.82M-$-36.68M-$-21.22M-$-22.82M-$-25.01M
EPSd-$-388.78K-$-512.51K-$-329.2K-$-365.06K-$-578.67K
Operating cash flow-$-23.85M-$-25.06M-$-25.18M-$-27.22M-$-23.55M
Capital expenditure-$-20K-$-20K-$-60K-$-70K-$-10K
Free cash flow-$-23.88M-$-25.08M-$-25.24M-$-27.3M-$-23.56M
Total assets$23.6M$31.9M$36.7M$45.8M$87.9M
Total debt$130K$160K$170K$50K$120K
Net debt-$-21.29M-$-30.42M-$-34.76M-$-43.77M-$-83.78M
Total equity$17.9M$24.7M$28.3M$38.5M$76.2M
Cash and short-term investments$21.4M$30.6M$34.9M$43.9M$83.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$60K
Cost of revenue$0.00$0.00$190K$160K$170K
Gross profit$0.00$0.00-$-190K-$-160K-$-110K
Research and development expenses$14M$14M$10.7M$14M$8.59M
Selling, general and administrative expenses$20.2M$25.9M$11.6M$16.3M$21.9M
Other expenses$100K$370K$0.00$0.00$0.00
Operating expenses$34.3M$40.3M$22.3M$30.3M$30.5M
Cost and expenses$34.3M$40.3M$22.5M$30.5M$30.6M
Interest income$730K$1.19M$2.04M$1.24M$110K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$100K$160K$190K$160K$170K
Ebitda-$-33.72M-$-36.52M-$-21.04M-$-22.66M-$-24.84M
Operating income-$-34.32M-$-40.28M-$-22.47M-$-30.49M-$-30.57M
Total other income/expenses, net$500K$3.6M$1.25M$7.68M$5.56M
Income before tax-$-33.82M-$-36.68M-$-21.22M-$-22.82M-$-25.01M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-33.82M-$-36.68M-$-21.22M-$-22.82M-$-25.01M
Weighted average shares outstanding$87M$71.6M$64.5M$62.5M$43.2M
Weighted average diluted shares outstanding$87M$71.6M$64.5M$62.5M$43.2M
Balance sheet
20252024202320222021
Cash and short-term investments$21.4M$30.6M$34.9M$43.9M$83.9M
Net receivables$230K$360K$280K$350K$70K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$23.5M$31.7M$36.2M$45.3M$87.1M
Property, plant and equipment, net$120K$200K$340K$220K$360K
Goodwill and intangible assets$0.00$0.00$210K$220K$380K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$120K$200K$550K$440K$740K
Total assets$23.6M$31.9M$36.7M$45.8M$87.9M
Accounts payable$3.48M$6.98M$7.62M$6.16M$4.14M
Short-term debt$40K$30K$20K$40K$40K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.66M$7.01M$8.3M$7.23M$11.6M
Long-term debt$90K$130K$160K$20K$70K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$90K$130K$160K$20K$70K
Capital lease obligations$130K$160K$170K$20K$120K
Total liabilities$5.74M$7.14M$8.45M$7.25M$11.6M
Common stock$201.9M$179.3M$148.5M$108.8M$142.9M
Retained earnings-$-213.07M-$-179.25M-$-142.58M-$-84.43M-$-83.52M
Accumulated other comprehensive income (loss)$0.00$0.00$3.52M$2.6M$4.18M
Total equity$17.9M$24.7M$28.3M$38.5M$76.2M
Total investments$0.00$0.00$0.00$50K$0.00
Total debt$130K$160K$170K$50K$120K
Net debt-$-21.29M-$-30.42M-$-34.76M-$-43.77M-$-83.78M
Cash flow statement
20252024202320222021
Net income-$-33.82M-$-36.68M-$-28.13M-$-30.93M-$-31.64M
Depreciation and amortization$100K$370K$250K$220K$220K
Stock-based compensation$10.7M$14.3M$4.16M$5.01M$8.5M
Change in working capital-$-730K-$-930K-$-550K$5.75M$80K
Accounts receivable$140K-$-80K$200K-$-140K-$-60K
Inventory$0.00$0.00$0.00-$-4.47M$20K
Accounts payable$0.00$0.00$0.00$4.47M$2.39M
Net cash provided by operating activities-$-23.85M-$-25.06M-$-25.18M-$-27.22M-$-23.55M
Investments in property, plant and equipment-$-20K-$-20K-$-60K-$-70K-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-20K-$-20K-$-60K-$-70K-$-10K
Common stock issued$16.1M$21.4M$0.00$0.00$84.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$15.5M$18.8M-$-60K-$-50K$93.4M
Net change in cash-$-9.16M-$-4.35M-$-24.54M-$-24.43M$69.9M
Cash at end of period$21.4M$30.6M$34.9M$59.5M$83.9M
Operating cash flow-$-23.85M-$-25.06M-$-25.18M-$-27.22M-$-23.55M
Capital expenditure-$-20K-$-20K-$-60K-$-70K-$-10K
Free cash flow-$-23.88M-$-25.08M-$-25.24M-$-27.3M-$-23.56M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cardiol Therapeutics Inc.

        Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.

        CEO
        David G. Elsley
        Employees
        18
        Beta
        0.51

        Explore

        Frequently asked questions

        What is the intrinsic value of Cardiol Therapeutics Inc. (CRDL)?

        InvestorsCraft does not currently publish an intrinsic value for CRDL. How the IC value is calculated.

        Is CRDL undervalued?

        InvestorsCraft does not publish an undervaluation signal for CRDL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.